UroGen Pharma (URGN) Inventory Average (2018 - 2026)

UroGen Pharma (URGN) has reported Inventory Average for 8 consecutive years, with $18.7 million the latest figure, recorded in Q1 2026.

• Quarterly Inventory Average rose 122.3% year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (up 122.3% YoY) and the FY2025 annual result came in at $12.8 million, up 72.42% from the prior year.
• Inventory Average climbed to $18.7 million in Q1 2026 per URGN's latest filing, from $12.4 million in the prior quarter.
• Over the last five years, Inventory Average for URGN reached as high as $18.7 million in Q1 2026 and fell as low as $4.6 million in Q4 2022.
• A 5-year average of $7.3 million and a median of $6.5 million in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2025 — Inventory Average advanced 0.22% — and 2026, when it soared 122.3%.
• Year by year, Inventory Average stood at $4.6 million in 2022, then rose by 16.2% to $5.3 million in 2023, then surged by 57.57% to $8.4 million in 2024, then soared by 47.46% to $12.4 million in 2025, then jumped by 50.72% to $18.7 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $18.7 million, $12.4 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.